FIELD: biotechnology.
SUBSTANCE: invention relates to a human monoclonal full-length antibody of subclass IgG1, which specifically binds to human TIGIT, to a composition and a kit containing it, as well as to a method for production thereof. Also disclosed is a polynucleotide coding said antibody, as well as a vector and a host cell containing it.
EFFECT: invention is effective for treating or slowing down the progression of cancer associated with TIGIT, as well as for treating or slowing down the progression of the immune system associated disease associated with TIGIT.
84 cl, 13 dwg, 17 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
